Geller David S, Gorlick Richard
Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY 10467, USA.
Clin Adv Hematol Oncol. 2010 Oct;8(10):705-18.
Despite significant advancements in the diagnosis and treatment of osteosarcoma to date, overall survival has remained relatively constant for over 2 decades. The challenge in osteosarcoma stems from the extreme variability from one tumor to the next, making it unlikely that a single target approach would be able to address all or even a majority of patients. Awareness, education, and proper referral patterns serve to minimize avoidable errors in diagnosis and treatment. However, it is unlikely that these efforts alone will significantly improve survival outcomes. Modern multi-agent chemotherapy has resulted in the greatest improvement in overall survival to date, and it is very likely that future improvements in survival will arise from combination-targeted chemotherapy in addition to conventional treatment.
尽管迄今为止骨肉瘤的诊断和治疗取得了重大进展,但20多年来总体生存率一直相对稳定。骨肉瘤的挑战源于肿瘤之间的极端变异性,使得单一靶点方法不太可能适用于所有甚至大多数患者。提高认识、开展教育以及建立适当的转诊模式有助于尽量减少诊断和治疗中可避免的错误。然而,仅靠这些努力不太可能显著改善生存结果。现代多药化疗是迄今为止总体生存率提高最大的因素,未来生存率的提高很可能来自于在传统治疗基础上联合靶向化疗。